Peder Sven Walberg
Director/Board Member at EGETIS THERAPEUTICS AB
Net worth: 21 M $ as of 30/03/2024
Profile
Dr. Peder Sven Walberg, MD, is a Chairman & Chief Executive Officer at TTM HoldCo AB.
He is on the Board of Directors at Egetis Therapeutics AB, Cetoros AB, Immedica Pharma AB and Immedica Pharma Holding AB.
Dr. Walberg was previously employed as a Chief Executive Officer & Director by Rare Thyroid Therapeutics International AB, an EVP-Business Development & Strategy by Swedish Orphan Biovitrum AB, a Head-Business Development & Licensing by Novartis AG, an EVP-Business Development & Strategy by Swedish Orphan International Holding AB, and a Management & Strategy Consultant by The Boston Consulting Group, Inc. He also served on the board at Wilson Therapeutics AB and OxThera AB.
He received his undergraduate degree from the University of Uppsala, an undergraduate degree from Swedish Armed Forces Language Institute and a doctorate degree from the University of Uppsala.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
EGETIS THERAPEUTICS AB
11.54% | 27/06/2023 | 33,776,221 ( 11.54% ) | 21 M $ | 30/03/2024 |
Peder Sven Walberg active positions
Companies | Position | Start |
---|---|---|
EGETIS THERAPEUTICS AB | Director/Board Member | 31/12/2019 |
Immedica Pharma AB
Immedica Pharma AB Medical DistributorsDistribution Services Immedica Pharma AB provides know-how and access of specialty care medicine and products. It also provides information on regulatory and medical affairs and product distribution. The company is headquartered in Stockholm, Sweden. | Founder | - |
Cetoros AB | Director/Board Member | - |
Immedica Pharma Holding AB | Director/Board Member | - |
TTM HoldCo AB | Chief Executive Officer | - |
Former positions of Peder Sven Walberg
Companies | Position | End |
---|---|---|
Rare Thyroid Therapeutics International AB
Rare Thyroid Therapeutics International AB BiotechnologyHealth Technology Rare Thyroid Therapeutics International AB provides thyroid therapeutics research services. The company is headquartered in Stockholm, Sweden. | Founder | 31/10/2020 |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Director/Board Member | 31/12/2015 |
WILSON THERAPEUTICS AB | Founder | 31/12/2014 |
SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | 31/12/2010 |
░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Peder Sven Walberg
University of Uppsala | Doctorate Degree |
Swedish Armed Forces Language Institute | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
NOVARTIS AG | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
EGETIS THERAPEUTICS AB | Health Technology |
Private companies | 9 |
---|---|
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | Health Technology |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
Immedica Pharma AB
Immedica Pharma AB Medical DistributorsDistribution Services Immedica Pharma AB provides know-how and access of specialty care medicine and products. It also provides information on regulatory and medical affairs and product distribution. The company is headquartered in Stockholm, Sweden. | Distribution Services |
Wilson Therapeutics AB
Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden. | Health Technology |
Rare Thyroid Therapeutics International AB
Rare Thyroid Therapeutics International AB BiotechnologyHealth Technology Rare Thyroid Therapeutics International AB provides thyroid therapeutics research services. The company is headquartered in Stockholm, Sweden. | Health Technology |
Cetoros AB | |
Immedica Pharma Holding AB | |
TTM HoldCo AB |
- Stock Market
- Insiders
- Peder Sven Walberg